Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada

Brian Chen, Sumimasa Nagai, James O. Armitage, Bartlett Witherspoon, Chadi Nabhan, Ashley C. Godwin, Y. Tony Yang, Anuhya Kommalapati, Sri Harsha Tella, Carlo DeAngelis, Dennis W. Raisch, Oliver Sartor, William J. Hrushesky, Paul S. Ray, Paul R. Yarnold, Bryan L. Love, Le Ann B. Norris, Kevin Knopf, Laura Bobolts, Joshua Riente & 4 others Stefano Luminari, Robert C. Kane, Shamia Hoque, Charles L. Bennett

Research output: Contribution to journalArticle

Abstract

Biosimilar filgrastims are primarily indicated for chemotherapy-induced neutropenia prevention. They are less expensive formulations of branded filgrastim, and biosimilar filgrastim was the first biosimilar oncology drug administered in European Union (EU) countries, Japan, and the U.S. Fourteen biosimilar filgrastims have been marketed in EU countries, Japan, the U.S., and Canada since 2008, 2012, 2015, and 2016, respectively. We reviewed experiences and policies for biosimilar filgrastim markets in EU countries and Japan, where uptake has been rapid, and in the U.S. and Canada, where experience is rapidly emerging. U.S. regulations for designating biosimilar interchangeability are under development, and such regulations have not been developed in most other countries. Pharmaceutical substitution is allowed for new filgrastim starts in some EU countries and in Canada, but not Japan and the U.S. In EU countries, biosimilar adoption is facilitated with favorable hospital tender offers. U.S. adoption is reportedly 24%, while the second filgrastim biosimilar is priced 30% lower than branded filgrastim and 20% lower than the first biosimilar filgrastim approved by the U.S. Food and Drug Administration. Utilization is about 60% in EU countries, where biosimilar filgrastim is marketed at a 30%–40% discount. In Japan, biosimilar filgrastim utilization is 45%, primarily because of 35% discounts negotiated by Central Insurance and hospital-only markets. Overall, biosimilar filgrastim adoption barriers are small in many EU countries and Japan and are diminishing in Canada in the U.S. Policies facilitating improved U.S. adoption of biosimilar filgrastim, based on positive experiences in EU countries and Japan, including favorable insurance coverage; larger price discount relative to reference filgrastim pricing; closing of the “rebate trap” with transparent pricing information; formal educational efforts of patients, physicians, caregivers, and providers; and allowance of pharmaceutical substitution of biosimilar versus reference filgrastim, should be considered. Implications for Practice: We reviewed experiences and policies for biosimilar filgrastims in Europe, Japan, Canada, and the U.S. Postmarketing harmonization of regulatory policies for biosimilar filgrastims has not occurred. Acceptance of biosimilar filgrastims for branded filgrastim, increasing in the U.S. and in Canada, is commonplace in Japan and Europe. In the U.S., some factors, accepted in Europe or Japan, could improve uptake, including acceptance of biosimilars as safe and effective; larger cost savings, decreasing “rebate traps” where pharmaceutical benefit managers support branded filgrastim, decreased use of patent litigation/challenges, and allowing pharmacists to routinely substitute biosimilar for branded filgrastim.

Original languageEnglish
JournalOncologist
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Biosimilar Pharmaceuticals
European Union
Canada
Japan
Filgrastim

Keywords

  • Biologics
  • Biosimilars
  • Chemotherapy
  • Filgrastim
  • Neutropenia
  • Patent

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. / Chen, Brian; Nagai, Sumimasa; Armitage, James O.; Witherspoon, Bartlett; Nabhan, Chadi; Godwin, Ashley C.; Yang, Y. Tony; Kommalapati, Anuhya; Tella, Sri Harsha; DeAngelis, Carlo; Raisch, Dennis W.; Sartor, Oliver; Hrushesky, William J.; Ray, Paul S.; Yarnold, Paul R.; Love, Bryan L.; Norris, Le Ann B.; Knopf, Kevin; Bobolts, Laura; Riente, Joshua; Luminari, Stefano; Kane, Robert C.; Hoque, Shamia; Bennett, Charles L.

In: Oncologist, 01.01.2019.

Research output: Contribution to journalArticle

Chen, B, Nagai, S, Armitage, JO, Witherspoon, B, Nabhan, C, Godwin, AC, Yang, YT, Kommalapati, A, Tella, SH, DeAngelis, C, Raisch, DW, Sartor, O, Hrushesky, WJ, Ray, PS, Yarnold, PR, Love, BL, Norris, LAB, Knopf, K, Bobolts, L, Riente, J, Luminari, S, Kane, RC, Hoque, S & Bennett, CL 2019, 'Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada', Oncologist. https://doi.org/10.1634/theoncologist.2018-0341
Chen, Brian ; Nagai, Sumimasa ; Armitage, James O. ; Witherspoon, Bartlett ; Nabhan, Chadi ; Godwin, Ashley C. ; Yang, Y. Tony ; Kommalapati, Anuhya ; Tella, Sri Harsha ; DeAngelis, Carlo ; Raisch, Dennis W. ; Sartor, Oliver ; Hrushesky, William J. ; Ray, Paul S. ; Yarnold, Paul R. ; Love, Bryan L. ; Norris, Le Ann B. ; Knopf, Kevin ; Bobolts, Laura ; Riente, Joshua ; Luminari, Stefano ; Kane, Robert C. ; Hoque, Shamia ; Bennett, Charles L. / Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. In: Oncologist. 2019.
@article{4e2d89c7f9014f5a83aa3f3b16c67e62,
title = "Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada",
abstract = "Biosimilar filgrastims are primarily indicated for chemotherapy-induced neutropenia prevention. They are less expensive formulations of branded filgrastim, and biosimilar filgrastim was the first biosimilar oncology drug administered in European Union (EU) countries, Japan, and the U.S. Fourteen biosimilar filgrastims have been marketed in EU countries, Japan, the U.S., and Canada since 2008, 2012, 2015, and 2016, respectively. We reviewed experiences and policies for biosimilar filgrastim markets in EU countries and Japan, where uptake has been rapid, and in the U.S. and Canada, where experience is rapidly emerging. U.S. regulations for designating biosimilar interchangeability are under development, and such regulations have not been developed in most other countries. Pharmaceutical substitution is allowed for new filgrastim starts in some EU countries and in Canada, but not Japan and the U.S. In EU countries, biosimilar adoption is facilitated with favorable hospital tender offers. U.S. adoption is reportedly 24{\%}, while the second filgrastim biosimilar is priced 30{\%} lower than branded filgrastim and 20{\%} lower than the first biosimilar filgrastim approved by the U.S. Food and Drug Administration. Utilization is about 60{\%} in EU countries, where biosimilar filgrastim is marketed at a 30{\%}–40{\%} discount. In Japan, biosimilar filgrastim utilization is 45{\%}, primarily because of 35{\%} discounts negotiated by Central Insurance and hospital-only markets. Overall, biosimilar filgrastim adoption barriers are small in many EU countries and Japan and are diminishing in Canada in the U.S. Policies facilitating improved U.S. adoption of biosimilar filgrastim, based on positive experiences in EU countries and Japan, including favorable insurance coverage; larger price discount relative to reference filgrastim pricing; closing of the “rebate trap” with transparent pricing information; formal educational efforts of patients, physicians, caregivers, and providers; and allowance of pharmaceutical substitution of biosimilar versus reference filgrastim, should be considered. Implications for Practice: We reviewed experiences and policies for biosimilar filgrastims in Europe, Japan, Canada, and the U.S. Postmarketing harmonization of regulatory policies for biosimilar filgrastims has not occurred. Acceptance of biosimilar filgrastims for branded filgrastim, increasing in the U.S. and in Canada, is commonplace in Japan and Europe. In the U.S., some factors, accepted in Europe or Japan, could improve uptake, including acceptance of biosimilars as safe and effective; larger cost savings, decreasing “rebate traps” where pharmaceutical benefit managers support branded filgrastim, decreased use of patent litigation/challenges, and allowing pharmacists to routinely substitute biosimilar for branded filgrastim.",
keywords = "Biologics, Biosimilars, Chemotherapy, Filgrastim, Neutropenia, Patent",
author = "Brian Chen and Sumimasa Nagai and Armitage, {James O.} and Bartlett Witherspoon and Chadi Nabhan and Godwin, {Ashley C.} and Yang, {Y. Tony} and Anuhya Kommalapati and Tella, {Sri Harsha} and Carlo DeAngelis and Raisch, {Dennis W.} and Oliver Sartor and Hrushesky, {William J.} and Ray, {Paul S.} and Yarnold, {Paul R.} and Love, {Bryan L.} and Norris, {Le Ann B.} and Kevin Knopf and Laura Bobolts and Joshua Riente and Stefano Luminari and Kane, {Robert C.} and Shamia Hoque and Bennett, {Charles L.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1634/theoncologist.2018-0341",
language = "English",
journal = "Oncologist",
issn = "1083-7159",
publisher = "Wiley Blackwell",

}

TY - JOUR

T1 - Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada

AU - Chen, Brian

AU - Nagai, Sumimasa

AU - Armitage, James O.

AU - Witherspoon, Bartlett

AU - Nabhan, Chadi

AU - Godwin, Ashley C.

AU - Yang, Y. Tony

AU - Kommalapati, Anuhya

AU - Tella, Sri Harsha

AU - DeAngelis, Carlo

AU - Raisch, Dennis W.

AU - Sartor, Oliver

AU - Hrushesky, William J.

AU - Ray, Paul S.

AU - Yarnold, Paul R.

AU - Love, Bryan L.

AU - Norris, Le Ann B.

AU - Knopf, Kevin

AU - Bobolts, Laura

AU - Riente, Joshua

AU - Luminari, Stefano

AU - Kane, Robert C.

AU - Hoque, Shamia

AU - Bennett, Charles L.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Biosimilar filgrastims are primarily indicated for chemotherapy-induced neutropenia prevention. They are less expensive formulations of branded filgrastim, and biosimilar filgrastim was the first biosimilar oncology drug administered in European Union (EU) countries, Japan, and the U.S. Fourteen biosimilar filgrastims have been marketed in EU countries, Japan, the U.S., and Canada since 2008, 2012, 2015, and 2016, respectively. We reviewed experiences and policies for biosimilar filgrastim markets in EU countries and Japan, where uptake has been rapid, and in the U.S. and Canada, where experience is rapidly emerging. U.S. regulations for designating biosimilar interchangeability are under development, and such regulations have not been developed in most other countries. Pharmaceutical substitution is allowed for new filgrastim starts in some EU countries and in Canada, but not Japan and the U.S. In EU countries, biosimilar adoption is facilitated with favorable hospital tender offers. U.S. adoption is reportedly 24%, while the second filgrastim biosimilar is priced 30% lower than branded filgrastim and 20% lower than the first biosimilar filgrastim approved by the U.S. Food and Drug Administration. Utilization is about 60% in EU countries, where biosimilar filgrastim is marketed at a 30%–40% discount. In Japan, biosimilar filgrastim utilization is 45%, primarily because of 35% discounts negotiated by Central Insurance and hospital-only markets. Overall, biosimilar filgrastim adoption barriers are small in many EU countries and Japan and are diminishing in Canada in the U.S. Policies facilitating improved U.S. adoption of biosimilar filgrastim, based on positive experiences in EU countries and Japan, including favorable insurance coverage; larger price discount relative to reference filgrastim pricing; closing of the “rebate trap” with transparent pricing information; formal educational efforts of patients, physicians, caregivers, and providers; and allowance of pharmaceutical substitution of biosimilar versus reference filgrastim, should be considered. Implications for Practice: We reviewed experiences and policies for biosimilar filgrastims in Europe, Japan, Canada, and the U.S. Postmarketing harmonization of regulatory policies for biosimilar filgrastims has not occurred. Acceptance of biosimilar filgrastims for branded filgrastim, increasing in the U.S. and in Canada, is commonplace in Japan and Europe. In the U.S., some factors, accepted in Europe or Japan, could improve uptake, including acceptance of biosimilars as safe and effective; larger cost savings, decreasing “rebate traps” where pharmaceutical benefit managers support branded filgrastim, decreased use of patent litigation/challenges, and allowing pharmacists to routinely substitute biosimilar for branded filgrastim.

AB - Biosimilar filgrastims are primarily indicated for chemotherapy-induced neutropenia prevention. They are less expensive formulations of branded filgrastim, and biosimilar filgrastim was the first biosimilar oncology drug administered in European Union (EU) countries, Japan, and the U.S. Fourteen biosimilar filgrastims have been marketed in EU countries, Japan, the U.S., and Canada since 2008, 2012, 2015, and 2016, respectively. We reviewed experiences and policies for biosimilar filgrastim markets in EU countries and Japan, where uptake has been rapid, and in the U.S. and Canada, where experience is rapidly emerging. U.S. regulations for designating biosimilar interchangeability are under development, and such regulations have not been developed in most other countries. Pharmaceutical substitution is allowed for new filgrastim starts in some EU countries and in Canada, but not Japan and the U.S. In EU countries, biosimilar adoption is facilitated with favorable hospital tender offers. U.S. adoption is reportedly 24%, while the second filgrastim biosimilar is priced 30% lower than branded filgrastim and 20% lower than the first biosimilar filgrastim approved by the U.S. Food and Drug Administration. Utilization is about 60% in EU countries, where biosimilar filgrastim is marketed at a 30%–40% discount. In Japan, biosimilar filgrastim utilization is 45%, primarily because of 35% discounts negotiated by Central Insurance and hospital-only markets. Overall, biosimilar filgrastim adoption barriers are small in many EU countries and Japan and are diminishing in Canada in the U.S. Policies facilitating improved U.S. adoption of biosimilar filgrastim, based on positive experiences in EU countries and Japan, including favorable insurance coverage; larger price discount relative to reference filgrastim pricing; closing of the “rebate trap” with transparent pricing information; formal educational efforts of patients, physicians, caregivers, and providers; and allowance of pharmaceutical substitution of biosimilar versus reference filgrastim, should be considered. Implications for Practice: We reviewed experiences and policies for biosimilar filgrastims in Europe, Japan, Canada, and the U.S. Postmarketing harmonization of regulatory policies for biosimilar filgrastims has not occurred. Acceptance of biosimilar filgrastims for branded filgrastim, increasing in the U.S. and in Canada, is commonplace in Japan and Europe. In the U.S., some factors, accepted in Europe or Japan, could improve uptake, including acceptance of biosimilars as safe and effective; larger cost savings, decreasing “rebate traps” where pharmaceutical benefit managers support branded filgrastim, decreased use of patent litigation/challenges, and allowing pharmacists to routinely substitute biosimilar for branded filgrastim.

KW - Biologics

KW - Biosimilars

KW - Chemotherapy

KW - Filgrastim

KW - Neutropenia

KW - Patent

UR - http://www.scopus.com/inward/record.url?scp=85062604487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062604487&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2018-0341

DO - 10.1634/theoncologist.2018-0341

M3 - Article

JO - Oncologist

JF - Oncologist

SN - 1083-7159

ER -